Form 4: Clover Health Director Boosts Stake with RSU Award

Clover Health director Thomas L. Tran was granted 79,365 Class A Common Stock shares through a restricted stock unit award, increasing his beneficial ownership to 180,029 shares.

Summary

• Thomas L. Tran, a Director of Clover Health Investments, Corp. (CLOV), acquired 79,365 shares of Class A Common Stock.
• The acquisition was made pursuant to an award of time-based Restricted Stock Units (RSUs).
• The RSUs will vest in full on January 6, 2027, which is the first anniversary of the grant date, contingent on Mr. Tran's continued service as a director.
• Following this transaction, Mr. Tran beneficially owns a total of 180,029 shares of Class A Common Stock.
• The transaction date for the RSU award was January 6, 2026, and the filing date was January 8, 2026.

Sentiment

Score: 7

Explanation: The grant of RSUs to a director is generally viewed positively as it increases insider ownership and aligns management's interests with shareholders, indicating confidence in the company's future.

Positives

• The grant of Restricted Stock Units to a director increases their equity stake in the company, aligning their interests more closely with those of shareholders.
• The vesting schedule encourages long-term commitment and continued service from the director.

Future Outlook

This filing does not contain forward-looking statements regarding the company's financial performance or strategic outlook, focusing solely on an insider's equity transaction.

Industry Context

Restricted Stock Unit (RSU) awards are a common form of equity compensation for directors and executives across various industries, particularly in the healthcare and technology sectors. These awards are designed to align the interests of company leadership with long-term shareholder value creation by tying compensation to the company's stock performance and requiring continued service.

Comparison to Industry Standards

• The grant of RSUs to a director is a standard practice for executive and director compensation in publicly traded companies, comparable to practices seen in other healthcare technology firms and growth-oriented companies.
• The time-based vesting schedule is typical for such awards, promoting retention and long-term commitment, similar to compensation structures at companies like Humana, UnitedHealth Group, or other health insurance providers with a technology focus.

Corporate Governance

Related Party Transactions

• The grant of 79,365 Restricted Stock Units to Thomas L. Tran, a director of Clover Health Investments, Corp., constitutes a related party transaction as it involves compensation provided to a member of the company's board.

Stakeholder Impact

• Shareholders: Increased alignment of director's interests with shareholder value due to a larger equity stake.
• Employees: No direct impact mentioned in this filing.
• Customers: No direct impact mentioned in this filing.
• Suppliers: No direct impact mentioned in this filing.
• Creditors: No direct impact mentioned in this filing.

Next Steps

• The 79,365 Restricted Stock Units are scheduled to vest in full on January 6, 2027, provided Thomas L. Tran continues his service as a director.

Key Dates

Keywords

Clover Health, CLOV, Thomas L. Tran, Director, Restricted Stock Units, RSU, Insider Transaction, Form 4, Equity Compensation, Beneficial Ownership